Tower Research Capital LLC (TRC), as stated in the most recent Form 13F filing that the company made with the Securities and Exchange Commission, increased its investment in Omnicell, INC (NASDAQ: OMCL) by 160.9% during the third quarter.

This information was gleaned from the filing that was made.

The institutional investor now possesses 4,234 shares of the company’s Stock after making an additional purchase of 2,611 shares during the preceding period.

This brings the total number of shares of the company’s stock that they own to 4,234.

At the end of the most recent reporting period, the value of the Omnicell interests that Tower Research Capital LLC (TRC) had was calculated to be $369,000.

Several hedge funds’ OMCL holdings have also been adjusted due to these changes.

During the third quarter, UBS Group AG increased the amount of Omnicell stock owned by 86.0 percent from the previous quarter. UBS Group AG now has a total of 9,143 shares, valued at $796k, following the purchase of an additional 4,228 shares during the most recent quarter.

Amalgamated Bank increased the proportion of Omnicell stock owned by 43.7% during the third quarter of the fiscal year.

Amalgamated Bank increased the number of shares it owned in the company at the beginning of the most recent quarter by purchasing 9,335 additional shares, bringing the total number of shares it owned in the company up to 30,717 has a value of $2,673,000. SVB Financial LLC made a new investment in Omnicell during the third quarter of the fiscal year.

The value of this investment was approximately $276,000.

During the third quarter, the investment portfolio managed by Aigen Investment Management LP saw a growth in its holdings of Omnicell equal to 40.5% over the previous quarter’s levels.

Aigen Investment Management LP now has 9,729 shares of the company’s stock, worth a combined total of $847,000 after making an additional purchase of 2,802 shares during the most recent quarter.

And finally, during the third quarter, the South Dakota Investment Council increased the amount of Omnicell stock owned by 35.0%, bringing its total ownership percentage to 80%.

The South Dakota Investment Council is now the owner of 13,527 shares in the company, which have a combined value of $1,177,000.

This is a result of the council’s purchase of 3,508 additional shares in the company during the most recent fiscal quarter.
The stock of OMCL has garnered the attention and commentary of several analysts.

In a research note made public on Friday, November 18, JPMorgan Chase & Co stated that they have decreased their target price on Omnicell shares to $57.00, a decrease from their previous price target of $140.00.

Despite this modification, the company has maintained its “neutral” rating with the investment firm. While maintaining their “overweight” rating on the stock, Wells Fargo & Company decreased their target price for Omnicell shares from $71.00 to $65.00 in a research report published on Tuesday, January 24.

The report was about the company’s outlook for the stock.
Regarding what course of action to take about Omnicell’s stock, the company advised readers to “hold” rather than “sell” in a research report made available by StockNews.com on Friday, January 13.

Piper Sandler upgraded their rating on Omnicell to “overweight” and increased their price objective on the stock from $55.00 to $66.00 in a research note published on Friday, January 27.

BTIG Research gave the company a “buy” rating in a report published on Thursday, November 3, and lowered its target price on Omnicell shares from $160.00 to $75.00.

The report was released after the market had closed.

The report was about the company recommended for purchase and included a “buy” rating.

There are a total of six analysts who have provided the company with a buy recommendation, while there are only three analysts who have provided it with a hold recommendation.

According to Bloomberg.com, the company is currently rated as a “Moderate Buy,” The website also reports that the target price for the company is currently rated as a consensus of $72.22.
As was stated earlier, Executive Vice President Scott Peter Seidelmann sold 945 shares of company stock on Tuesday, December 27.

This sale took place as previously mentioned.

As a direct result of the transaction, the executive vice president now owns 29,788 company shares with a combined value of $1,438,164.64.

The shares were sold on the open market for a total price of $48.28 per share, totaling $45,624.60. One can access a document that provides additional information on the transaction by going to the Securities and Exchange Commission (SEC) website. On December 1, Omnicell’s Chief Executive Officer, Randall A.

Lipps, sold 2,500 of the company’s shares of stock, which brings us to another piece of Omnicell-related news.

The price per share, sold at an average of $50.78, brought in a total of $126,950.00 for the transaction’s volume.

As a direct consequence of the transaction, the Chief Executive Officer now owns 88,348 shares.

The total value of these shares is approximately 4,486,311.44 dollars. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC relating to the transaction.

This information is currently available.
Additionally, on December 27, 2018, Executive Vice President Scott Peter Seidelmann sold 945 shares of company stock.

The shares were sold on the open market for $48.28 each, bringing the total to $45,624.60.

The executive vice president now owns 29,788 shares of the company, which have a value of approximately $1,438,164.64 due to the transaction.

Disclosures related to the sale might be found in this website section. Over the past three months, company insiders have parted ways with 7,881 shares, realizing a combined profit of $384,571.

The company insiders’ current ownership of the company’s stock is 2.76%.

When trading started on Tuesday, OMCL stock was $52.96 per share. Over the last 52 weeks, the highest and lowest prices for Omnicell, INC have been equal, coming in at $138.50.

The company currently has a simple moving average of $53.70 for the past 50 days and a simple moving average of $68.49 for the past 200 days.

The debt-to-equity ratio comes in at 0.50, the quick ratio at 1.86, the current ratio at 2.25, and the quick ratio at 1.86.

The company’s market capitalization is at a very healthy 2.35 billion dollars.

It has a price-to-earnings ratio of 51.92, a price-to-earnings-growth ratio of 5.25, and a beta value of 0.92.

These metrics all point toward the company’s potential for future expansion.

Omnicell, INC gives establishments like hospitals and pharmacies access to adherence tools and automated medication management solutions. Omnicell provides these solutions.

A few problems that can be solved with this technology include medication compliance, central pharmacy dispensing, point-of-care automation, intelligence, platform and interoperability, and population health.

The post Tower Research Capital LLC TRC has acquired Omnicell, Inc. (NASDAQ:OMCL) shares. appeared first on Best Stocks.